动脉端与静脉端给药那屈肝素预防血液透析滤过体外循环血栓的比较
结果显示静脉端给药可显著降低抗凝剂剂量并改善透析性能。
要点
- 静脉端给药较动脉端显著减少那屈肝素用量
- 静脉端给药组滤器凝血率更低,透析充分性改善
- 在线血液透析滤过时抗凝剂给药部位影响药物清除与疗效
核心结论
- 在线血液透析滤过时经静脉端单次给予那屈肝素钙可显著减少剂量并改善透析性能。
主要发现
- 静脉壶清洁比例分别为75%、93%、95%,滤器凝血率分别为9%、0.6%、0.4%。
- 阶段I平均那屈肝素剂量0.43 ml,阶段II为0.3 ml;阶段III中15例剂量减少33%至50%。
- 阶段III Kt/V从1.64升至1.75,置换液量从20.18 L增至21.96 L。
临床怎么用
- 在线血液透析滤过时可考虑经静脉端给予那屈肝素以减少剂量并改善透析效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Administration of low-molecular-weight heparins (LMWHs) is necessary for preventing extracorporeal circuit thrombosis during hemodialysis. A substantial amount of LMWH is removed with online hemodiafiltration (OL-HDF) when administered through the inlet site of the extracorporeal circuit. Consequently, administration of LMWH at the outlet site appears to be more efficient. In this study we aimed to compare the effects of nadroparin calcium (NAD) administered through the outlet versus the inlet port site in postdilution OL-HDF and assess the NAD dose reduction. METHODS: Forty-nine hemodialysis patients were included in 3 consecutive 6-week studies as follows: phase I, inlet port line; phase II, outlet port line; and phase III, outlet port line with reduced dose. We evaluated clotting in the hemodialyzer and venous bubble trap, the dialysis dose (K t/V), and substitution volume. RESULTS: Thirty four percent, 63%, and 66% were categorized as "white" during phases I, II, and III, respectively. During phases I, II, and III, 75%, 93%, and 95% of the venous bubble traps were "clean," and 9%, 0.6%, and 0.4% of the dialyzers clotted, respectively. Average NAD dose was 0.43 ml during phase I and 0.3 ml during phase II. During phase III, the LMWH dose was reduced by 33% to 50% in 15 patients. In phase III, Kt/V improved from 1.64 to 1.75 and substitution volume increased from 20.18 to 21.96 L. CONCLUSIONS: When using OL-HDF, a single administration of NAD at the outlet port line allows for a significant dose reduction and was associated with improved dialysis performance.
引用
- Hebibi H, Attaf D, Cornillac L, et al. Arterial Versus Venous Port Site Administration of Nadroparin for Preventing Thrombosis of Extracorporeal Blood Circuits in Patients Receiving Hemodiafiltration Treatment. Kidney Int Rep. 2020. PMID: 33615060. doi:10.1016/j.ekir.2020.11.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。